Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients: Insights from the Statistical Analysis of Survey Data
- PMID: 39766549
- PMCID: PMC11672620
- DOI: 10.3390/antibiotics13121160
Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients: Insights from the Statistical Analysis of Survey Data
Abstract
Background: Empirical antibacterial therapy for febrile neutropenia reduces mortality due to Gram-negative blood stream infections (BSIs). Pediatric guidelines recommend monotherapy with an antipseudomonal beta-lactam or a carbapenem and to add a second anti-Gram-negative agent in selected situations. We evaluated the changes in the proportions of resistance of beta-lactam monotherapies vs. their combination with amikacin, and the possible impact on ICU admission or death. Results: 797 BSIs due to Gram-negative bacteria in 685 patients were included. Combination therapies with amikacin had a lower percentage of isolates resistant to one or to both drugs compared with the respective monotherapy. The highest OR for ICU admission was observed when both drugs of the combination of meropenem-amikacin were resistant. Mortality was significantly associated with relapse or the progression of the underlying malignancy, and resistance to both drugs of the combinations of cefepime-amikacin or meropenem-amikacin. Methods: This study was based on data collected for a large multinational study, in which the susceptibility of Gram-negative bloodstream isolates was categorized following either EUCAST or CLSI according to local laboratory standards. An escalation antibiogram was generated for each selected drug. For resistant bacteria, the conditional susceptibility probability on resistance was calculated. Conclusions: In pediatric cancer patients with Gram-negative BSIs, the proportion of the resistant organism correlates with ICU admission or death, which may be reduced by combination therapy. In patients with suspected or confirmed Gram-negative BSIs that are not-improving or deteriorating under monotherapy, escalation to meropenem may represent the best option. Amikacin should be preferred when combination therapy is considered with ciprofloxacin as an alternative in the case of impaired renal function.
Keywords: Gram-negative bacteriamia; combination therapy; empiric antibiotic therapy; febrile neutropenia.
Conflict of interest statement
Author Roland A. Ammann was employed by the company StatConsult Ammann. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Antibiotic susceptibility of Gram-negatives isolated from bacteremia in children with cancer. Implications for empirical therapy of febrile neutropenia.Future Microbiol. 2015;10(3):357-64. doi: 10.2217/fmb.14.144. Future Microbiol. 2015. PMID: 25812459
-
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.Ann Hematol. 1998 Feb;76(2):73-80. doi: 10.1007/s002770050366. Ann Hematol. 1998. PMID: 9540761 Clinical Trial.
-
Introducing the Escalation Antibiogram: A Simple Tool to Inform Changes in Empiric Antimicrobials in the Nonresponding Patient.Clin Infect Dis. 2022 Nov 14;75(10):1763-1771. doi: 10.1093/cid/ciac256. Clin Infect Dis. 2022. PMID: 35380628
-
Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis.J Matern Fetal Neonatal Med. 2022 Mar;35(5):861-870. doi: 10.1080/14767058.2020.1732342. Epub 2020 Feb 26. J Matern Fetal Neonatal Med. 2022. PMID: 32102584 Review.
-
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.
Cited by
-
European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet-INNOCHRON COST Action based on a systematic evidence review.Hemasphere. 2025 Apr 16;9(4):e70113. doi: 10.1002/hem3.70113. eCollection 2025 Apr. Hemasphere. 2025. PMID: 40242664 Free PMC article.
References
-
- Lehrnbecher T., Averbuch D., Castagnola E., Cesaro S., Ammann R.A., Garcia-Vidal C., Kanerva J., Lanternier F., Mesini A., Mikulska M., et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22:e270–e280. doi: 10.1016/S1470-2045(20)30725-7. - DOI - PubMed
-
- Averbuch D., Orasch C., Cordonnier C., Livermore D.M., Mikulska M., Viscoli C., Gyssens I.C., Kern W.V., Klyasova G., Marchetti O., et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–1835. doi: 10.3324/haematol.2013.091025. - DOI - PMC - PubMed
-
- Castagnola E., Fontana V., Caviglia I., Caruso S., Faraci M., Fioredda F., Garrè M.L., Moroni C., Conte M., Losurdo G., et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin. Infect. Dis. 2007;45:1296–1304. doi: 10.1086/522533. - DOI - PubMed
LinkOut - more resources
Full Text Sources